前列腺健康市場規模、佔有率和成長分析：按疾病、治療方法、最終用戶、銷售管道、通路和地區分類－2026-2033年產業預測

2024 年全球攝護腺健康市場價值為 360.1 億美元，預計到 2025 年將成長至 393.2 億美元，到 2033 年將成長至 793.8 億美元，在預測期（2026-2033 年）內複合年成長率為 9.18%。

全球攝護腺健康市場受到攝護腺疾病（尤其是良性攝護腺增生和攝護腺癌）日益成長的盛行率的顯著影響，這推動了對診斷、治療和篩檢計畫的需求。該市場涵蓋藥品、診斷工具（如PSA檢測和MRI融合切片檢查）、微創手術器械和補充劑。人口老化和公眾健康意識的提高給醫療保健系統帶來了臨床和經濟壓力。從被動治療向早期檢測和個人化醫療的重大轉變，推動了多參數MRI和主動監測方案的普及。診斷和治療技術的進步，例如檢測靈敏度的提高和微創治療方案的出現，進一步提高了患者的接受度和保險公司的支持，刺激了對創新生物標記、數位化工具和遠距遠端醫療服務的投資，以滿足老年人的需求。

全球攝護腺健康市場的成長要素

老年男性數量的不斷成長顯著增加了前列腺疾病的高危險群數量，進而推動了對診斷服務、治療方案和長期管理選擇的需求。隨著患者對篩檢和治療重要性的認知不斷提高，醫療保健產業的相關人員正優先開發和推廣創新診斷工具、微創療法和病患監測技術。這些人口結構的變化促使企業加強對產品系列的投入，而公眾對這些產品和服務的認知度不斷提高，預計將透過各種臨床護理和服務管道，進一步推動整個市場的成長。

全球攝護腺健康市場面臨的限制因素

先進治療方法、診斷程序和持續患者管理的高昂費用帶來了成本效益的挑戰，影響了醫療服務的可近性，並降低了新產品的採用率。當保險公司不願意提供充足的報銷或實施限制性承保政策時，醫療專業人員可能傾向於選擇成熟的、經濟有效的替代方案，而不是採用創新解決方案。這些財務限制也會阻礙中小企業進入市場，並抑制對研發和分銷的投資。因此，這些因素共同限制了前列腺健康領域的整體市場成長和先進臨床服務的引入。

全球攝護腺健康市場趨勢

全球前列腺健康市場正經歷著向遠端醫療和遠端監測的顯著轉變，這從根本上改變了患者參與度和護理的連續性。線上諮詢和家庭監測的引入，提高了前列腺健康問題的早期發現和管理，並實現了患者與醫療服務提供者之間的無縫溝通。這一趨勢正在消除地域限制，促進積極主動的健康行為，並推動多學科協作。隨著保險公司和醫療系統優先考慮線上診療路徑以改善醫療服務可及性和最佳化資源配置，供應商正致力於開發可互通的平台，使臨床工作流程與以患者為中心的遠距服務模式相契合，這展現了市場的蓬勃發展。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球攝護腺健康市場規模：依疾病適應症分類

• 良性攝護腺增生
• 攝護腺癌
• 攝護腺炎

全球攝護腺健康市場規模：依治療方法分類

• 治療藥物和藥品
  • α受體阻斷劑
  • 5α-還原酶抑制劑
  • 分子標靶癌症療法
• 營養補充品和草藥萃取物
• 外科手術及微創設備

全球攝護腺健康市場規模：依最終用戶分類

• 醫院及腫瘤中心
• 泌尿系統診所
• 居家照護環境

全球攝護腺健康市場規模：依銷售管道分類

• 線上
• 離線

全球前列腺健康市場規模：按分銷管道分類

• 直接的
• 間接

全球攝護腺健康市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline
• Pfizer
• Sanofi
• Merck & Co
• AstraZeneca
• Eli Lilly and Company
• Johnson & Johnson
• AbbVie
• Takeda Pharmaceutical
• Astellas Pharma
• Asahi Kasei
• Teijin Limited
• Allergan
• Boehringer Ingelheim
• Kyorin Pharmaceutical
• Sawai Pharmaceutical
• Towam Pharmaceutical
• Meiji Holdings
• Shionogi
• Ono Pharmaceutical

結論與建議

Global Prostate Health Market size was valued at USD 36.01 Billion in 2024 and is poised to grow from USD 39.32 Billion in 2025 to USD 79.38 Billion by 2033, growing at a CAGR of 9.18% during the forecast period (2026-2033).

The global prostate health market is significantly influenced by the increasing prevalence of prostate disorders, notably benign prostatic hyperplasia and prostate cancer, driving the demand for diagnostics, therapeutics, and screening programs. This market encompasses pharmaceuticals, diagnostic tools like PSA testing and MRI fusion biopsy, minimally invasive surgical devices, and supplements. The aging population and heightened awareness create both clinical and economic pressures for health systems. A notable shift from reactive treatment to early detection and personalized care enhances the adoption of multiparametric MRI and active surveillance protocols. Technological advancements in diagnostics and therapeutics, including improved test sensitivities and less invasive treatment options, further boost patient uptake and payer support, prompting investments in innovative biomarkers, digital tools, and telehealth services to meet the needs of older demographics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prostate Health market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Prostate Health Market Segments Analysis

Global prostate health market is segmented by disease indication, treatment modality, end-user, sales channel, distribution channel and region. Based on disease indication, the market is segmented into benign prostatic hyperplasia, postate cancer and prostatitis. Based on treatment modality, the market is segmented into therapeutics & pharmaceuticals, dietary supplements & herbal extracts and surgical & minimally invasive devices. Based on end-user, the market is segmented into hospitals & oncology centers, urology clinics and homecare settings. Based on sales channel, the market is segmented into online and offline. Based on distribution channel, the market is segmented into direct and indirect. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Prostate Health Market

The growing population of older males is significantly contributing to an increase in individuals at risk for prostate diseases, which, in turn, drives the demand for diagnostic services, treatment solutions, and long-term management options. This rising awareness among patients about the importance of screening and treatment has prompted stakeholders across the healthcare sector to prioritize the development and distribution of innovative diagnostic tools, minimally invasive therapies, and patient monitoring technologies. Such demographic changes are prompting investment in enhanced product portfolios, and raising awareness of these offerings is likely to facilitate broader growth across the entire market through various clinical care and service delivery channels.

Restraints in the Global Prostate Health Market

Significant costs related to advanced therapies, diagnostic procedures, and ongoing patient management pose challenges to affordability, consequently impacting access to care and diminishing the adoption rate of new products. When insurance providers express reluctance to offer thorough reimbursement or implement restrictive coverage policies, healthcare professionals may lean toward established, cost-effective alternatives instead of embracing innovative solutions. These financial limitations can also deter smaller companies from entering the market and hinder investments in research and distribution initiatives. As a result, these factors collectively restrict overall market growth and the integration of enhanced clinical offerings within the prostate health sector.

Market Trends of the Global Prostate Health Market

The Global Prostate Health market is witnessing a significant shift towards telehealth and remote monitoring, fundamentally transforming patient engagement and care continuity. The adoption of virtual consultations and at-home monitoring is enhancing early detection and management of prostate health issues, enabling seamless communication between patients and healthcare providers. This trend is breaking down geographic barriers, fostering proactive health behaviors, and encouraging multidisciplinary collaboration. As payers and health systems emphasize virtual care pathways to improve access and resource optimization, technology vendors are focusing on developing interoperable platforms that align clinical workflows with patient-centered remote service delivery models, indicating a robust market evolution.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Prostate Health Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Benign Prostatic Hyperplasia
• Prostate Cancer
• Prostatitis

Global Prostate Health Market Size by Treatment Modality & CAGR (2026-2033)

• Market Overview
• Therapeutics & Pharmaceuticals
  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Targeted Oncology Drugs
• Dietary Supplements & Herbal Extracts
• Surgical & Minimally Invasive Devices

Global Prostate Health Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Oncology Centers
• Urology Clinics
• Homecare Settings

Global Prostate Health Market Size by Sales Channel & CAGR (2026-2033)

• Market Overview
• Online
• Offline

Global Prostate Health Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct
• Indirect

Global Prostate Health Market Size & CAGR (2026-2033)

• North America (Disease Indication, Treatment Modality, End-User, Sales Channel, Distribution Channel)
  • US
  • Canada
• Europe (Disease Indication, Treatment Modality, End-User, Sales Channel, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Indication, Treatment Modality, End-User, Sales Channel, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Indication, Treatment Modality, End-User, Sales Channel, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Indication, Treatment Modality, End-User, Sales Channel, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teijin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyorin Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sawai Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Towam Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meiji Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations